Equities research analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a research note issued on Thursday. The firm set a “sell” rating on the stock.
A number of other equities analysts also recently weighed in on ONCT. Maxim Group downgraded shares of Oncternal Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 4th. Brookline Capital Management lowered Oncternal Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. HC Wainwright downgraded Oncternal Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, April 4th. Oppenheimer downgraded Oncternal Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 4th. Finally, Brookline Capital Acquisition reiterated a “hold” rating on shares of Oncternal Therapeutics in a report on Tuesday, April 4th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.77.
Oncternal Therapeutics Stock Performance
Shares of ONCT opened at $0.31 on Thursday. Oncternal Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.52. The stock has a fifty day moving average of $0.34 and a two-hundred day moving average of $0.76. The company has a market capitalization of $18.14 million, a PE ratio of -0.37 and a beta of 1.54.
Insider Activity
In other Oncternal Therapeutics news, CEO James B. Breitmeyer bought 100,000 shares of the stock in a transaction dated Thursday, April 13th. The stock was bought at an average cost of $0.29 per share, for a total transaction of $29,000.00. Following the completion of the purchase, the chief executive officer now directly owns 146,544 shares of the company’s stock, valued at $42,497.76. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders bought 160,000 shares of company stock worth $46,650. 8.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Oncternal Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of ONCT. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Oncternal Therapeutics during the 1st quarter valued at approximately $585,000. Vanguard Group Inc. raised its stake in Oncternal Therapeutics by 9.0% during the first quarter. Vanguard Group Inc. now owns 2,325,515 shares of the company’s stock worth $3,232,000 after acquiring an additional 192,189 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Oncternal Therapeutics by 44.4% during the first quarter. Renaissance Technologies LLC now owns 543,800 shares of the company’s stock valued at $756,000 after purchasing an additional 167,268 shares during the last quarter. Mirabella Financial Services LLP bought a new stake in shares of Oncternal Therapeutics in the 1st quarter worth approximately $38,000. Finally, UBS Group AG increased its position in Oncternal Therapeutics by 1,373.8% in the second quarter. UBS Group AG now owns 166,298 shares of the company’s stock worth $184,000 after buying an additional 155,014 shares during the period. Institutional investors own 16.66% of the company’s stock.
Oncternal Therapeutics Company Profile
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Featured Articles
- Get a free copy of the StockNews.com research report on Oncternal Therapeutics (ONCT)
- What is a Growth Stock Mutual Fund?
- 10 Best Airline Stocks to Buy
- Ollie’s Bargain Outlet Goes On Sale
- Campbell Soup Company Leads Staples Stocks Into The Buy Zone
- Netflix Collaboration Fuels IAS, DoubleVerify Stock Surge
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
